Effects of Eprosartan on Target Organ Protection

References

• AngeliFVerdecchiaPReboldiGPCalcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjectsAm J Hypertens2004178172215363825
   PubMed Web of Science ®Google Scholar
• ArosioEDe MarchiSPriorMHaemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stressJ Hypertens2005231923716148617
   PubMed Web of Science ®Google Scholar
• BaltJMathyMJPfaffendorfMInhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartanJ Hypertens20011922415011725169
   PubMed Web of Science ®Google Scholar
• BaroneFCCoatneyRWChandraSEprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone ratsCardiovas Res20015052537
   PubMed Web of Science ®Google Scholar
• BehrTMWilletteRNCoatneyRWEprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart diseaseJ Hypertens2004225839215076165
   PubMed Web of Science ®Google Scholar
• BlankenbergSRupprechtHJBickelCCirculating cell adhesion molecules and death in patients with coronary artery diseaseCirculation200110413364211560847
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureJAMA200328925607212748199
   PubMed Web of Science ®Google Scholar
• CollinsRPetoRMacMahonSBlood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological contextLancet1990335827381969567
   PubMed Web of Science ®Google Scholar
• DahlöfBDvereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• De GasparoMCattKJInagamiTInternational Union of Pharmacology. XXIII. The angiotensin II receptorsPharmacol Rev2000524157210977869
   PubMed Web of Science ®Google Scholar
• De RosaGRagonesiPDMugelliniAEffects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month studyHypertens Res2004274576415302981
   PubMed Web of Science ®Google Scholar
• DevereuxRBWachtellKGerdtsEPrognostic significance of left ventricular mass change during treatment of hypertensionJAMA20042922350615547162
   PubMed Web of Science ®Google Scholar
• ElliottWJDouble-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patientsJ Human Hypertens1999134131710408592
   PubMed Web of Science ®Google Scholar
• FliserDBuchholzKHallerHAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation20041101103715313950
   PubMed Web of Science ®Google Scholar
• FournierAMesserliFHAchardJMCerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trialsJ Am Coll Cardiol2004431343715093864
   PubMed Web of Science ®Google Scholar
• Garcia PuigJMateosFBuñoAEffect of eprosartan and losartan on Eric acid metabolism in patients with essential hypertensionJ Hypertens1999171033910419078
   PubMed Web of Science ®Google Scholar
• [GC] Guidelines CommitteeEuropean Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032110115312777938
   PubMed Web of Science ®Google Scholar
• GuimaraesSPinheiroHTavaresPDifferential effects of eprosartan and losartan at prejunctional angiotensin II receptorsNaunyn-Schmiedebergs Arch Pharmacol20013635091411383711
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KjeldsenSEJuliusSHednerTStroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trialsBlood Pr2001101902
   PubMed Web of Science ®Google Scholar
• KleinIHLigtenbergGOeyPLEnalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failureJ Asm Soc Nephrol20031442530
   PubMed Web of Science ®Google Scholar
• KohKKAhnJYHanSHPleiotropic effects of angiotensin II receptor blocker in hypertensive patientsJ Am Coll Cardiol2003429051012957441
   PubMed Web of Science ®Google Scholar
• LabiosMMartinezMGabrielFEffect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertensionAm J Hypertens2004177576315363816
   PubMed Web of Science ®Google Scholar
• LeuHBCharngMJDingPYA double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertensionJpn Heart J2004456233515353873
   PubMedGoogle Scholar
• LewingtonSClarkeRQizilbashNProspective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236019031312493255
   PubMed Web of Science ®Google Scholar
• LiJCulmanJHortnaglHAngiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injuryFASEB J2005196171915665034
   PubMed Web of Science ®Google Scholar
• LibbyPRidkerPMMaseriAInflammation and atherosclerosisCirculation200210511354311877368
   PubMed Web of Science ®Google Scholar
• LigtenbergGBlankestijnPJOeyPLReduction of sympathetic hyperactivity by enalapril in patients with chronic renal failureN Engl J Med19993401321810219067
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens2003218758812714861
   PubMed Web of Science ®Google Scholar
• MakrisTKStavroulakisGPapadoppoulosDPEprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartanDrugs Exp Clin Res2004301253215366789
   PubMedGoogle Scholar
• NakashimaHKumagaiKUrataHAngiotensin II antagonist prevents electrical remodeling in atrial fibrillationCirculation10126121710840013
   PubMed Web of Science ®Google Scholar
• OhlsteinEHBrooksDPFeuersteinGZInhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockadePharmacology199755244519399334
   PubMed Web of Science ®Google Scholar
• OkinPMDevereuxRBJernSRegression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular eventsJAMA20042922343915547161
   PubMed Web of Science ®Google Scholar
• PerticoneFCeravoloRPujiaAPrognostic significance of endothelial dysfunction in hypertensive patientsCirculation2001104191611447085
   PubMed Web of Science ®Google Scholar
• PloskerGLFosterRHEprosartan: a review of its use in the management of hypertensionDrugs20006017720110929934
   PubMed Web of Science ®Google Scholar
• [PROGRESS] PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attackLancet200135810334111589932
   PubMed Web of Science ®Google Scholar
• RahmanSTLautenWBKhanQAEffects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation)Am J Cardiol2002896869011897210
   PubMed Web of Science ®Google Scholar
• RobinsGWScottLJEprosartan. A review of its use in the management of hypertensionDrugs20056523557716266204
   PubMed Web of Science ®Google Scholar
• RuilopeLMJagerBPrichardBEprosartan versus enalapril in elderly patients with hypertension: a double-blind randomized trialBlood Pr2001102239
   PubMed Web of Science ®Google Scholar
• SchächingerVBrittenMZeiherAMPrognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart diseaseCirculation2000101189990610779454
   PubMed Web of Science ®Google Scholar
• SchiffrinELParkJBIntenganHDCorrection of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartanCirculation20001011653910758046
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulchewskiAThe ACCESS study. Evaluation of acute candesartan cilexetil therapy in stroke survivorsStroke200334169970312817109
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAMorbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES)Stroke20053612182615879332
   PubMed Web of Science ®Google Scholar
• SierraCde la SierraAAntihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockersCurr Opin Nephrol Hypertens2005144354116046901
   PubMed Web of Science ®Google Scholar
• SegaREfficacy and safety of eprosartan in severe hypertensionBlood Pr1999811421
   PubMed Web of Science ®Google Scholar
• StaessenJAFagardRThijsLRandomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionLancet1997350757649297994
   PubMed Web of Science ®Google Scholar
• StaessenJAGasowskiJWangJGRisks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trialsLancet20003558657210752701
   PubMed Web of Science ®Google Scholar
• StruckJMuckPTrübgerDEffects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjectsJ Hypertens2002201143912023684
   PubMed Web of Science ®Google Scholar
• TurnbullFBlood Pressure Lowering Treatment Trialists' CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336215273514615107
   PubMed Web of Science ®Google Scholar
• VasanRSBeiserASeshadriSResidual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart StudyJAMA200228710031011866648
   PubMed Web of Science ®Google Scholar
• WachtellKLehtoMGerdtsEAngiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyJ Am Coll Cardiol2005457121915734615
   PubMed Web of Science ®Google Scholar
• WangJGStaessenJAGongLChinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative GroupArch Intern Med1602112010647760
   PubMedGoogle Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United StatesJAMA20032892363912746359
   PubMed Web of Science ®Google Scholar